Breaking News, Financial News

Financial Report: Ligand

Revenues up 56% in the quarter driven by Captisol

Ligand

4Q Revenues: $23.0 million (+56%)

4Q Earnings: $7.1 million (+278%)

FY Revenues: $64.5 million (+32%)

FY Earnings: $12.0 million (+5%)

Comments: Royalty revenues increased 32% in the quarter to $9.4 million primarily due to higher royalties from Promaca and Kyprolis. Material sales increased to $13.0 million from $6.8 million in 4Q13 due to higher demand for Captisol for both clinical and commercial uses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters